Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12624001100583
Ethics application status
Approved
Date submitted
18/06/2024
Date registered
12/09/2024
Date last updated
12/09/2024
Date data sharing statement initially provided
12/09/2024
Type of registration
Prospectively registered
Titles & IDs
Public title
A Study to Determine the Effects of Dual Anti-Platelet Therapy (DAPT) on Neutrophils.
Query!
Scientific title
A Study to Determine the Effects of in vivo Dual Anti-Platelet Therapy (DAPT) on Neutrophils.
Query!
Secondary ID [1]
312358
0
None
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Neutrophil response to aspirin and ticagrelor in healthy volunteers
335023
0
Query!
Condition category
Condition code
Inflammatory and Immune System
330813
330813
0
0
Query!
Normal development and function of the immune system
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Dual antiplatelet therapy (DAPT): Acetylsalicylic acid (Aspirin) and ticagrelor.
The proposed study is to investigate whether neutrophils are affected by dual antiplatelet therapy.
Participants will receive DAPT (oral tablets) for a total of seven days. Participants will receive a combination of Acetylsalicylic acid (300 mg loading dose on day 1, 100 mg maintenance dose on days 2 – 7) and ticagrelor (180 mg loading dose on day 1, 90 mg maintenance dose on days 1 – 7). This treatment regime mimics the routine administration of DAPT for acute myocardial infarction (AMI) patients in Aotearoa New Zealand. Adherence to medication will be recorded by participants (date and time of dose) and checked by the study researchers at each study visit. Participants are also informed that non-adherence at any point during the 7 day study period will result in withdrawal from the study.
After Day 1 (loading doses), participants will self-administer DAPT and record timing and dates of each dose in a provided form. Participants can also choose to be notified when it is time to take their next dose of DAPT.
Query!
Intervention code [1]
328855
0
Treatment: Drugs
Query!
Comparator / control treatment
A blood sample will be collected from each participant pre-intervention (DAPT) and this sample will act as a control and no additional treatment arm is required.
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
338577
0
Neutrophil immunophenotyping
Query!
Assessment method [1]
338577
0
Multicolour spectral flow cytometry
Query!
Timepoint [1]
338577
0
Baseline, 24-hours post-commencement of DAPT, 7-days post-commencement of DAPT.
Query!
Primary outcome [2]
339278
0
Phagocytosis capacity
Query!
Assessment method [2]
339278
0
Flow cytometry (E. coli-pHrodo Green Bioparticles)
Query!
Timepoint [2]
339278
0
Baseline, 24-hours post-commencement of DAPT, 7-days post-commencement of DAPT.
Query!
Primary outcome [3]
339279
0
Superoxide anion production
Query!
Assessment method [3]
339279
0
Colorimetric analysis of WST-1 products.
Query!
Timepoint [3]
339279
0
Baseline, 24-hours post-commencement of DAPT, 7-days post-commencement of DAPT.
Query!
Secondary outcome [1]
436495
0
Platelet function
Query!
Assessment method [1]
436495
0
Light transmission aggregometry
Query!
Timepoint [1]
436495
0
24-hours post-commencement of DAPT, 7-days post-commencement of DAPT.
Query!
Secondary outcome [2]
439348
0
Release of soluble mediators
Query!
Assessment method [2]
439348
0
Cytometric bead array (CBA) - this is an additional primary outcome.
Query!
Timepoint [2]
439348
0
Baseline, 24-hours post-commencement of DAPT, 7-days post-commencement of DAPT.
Query!
Eligibility
Key inclusion criteria
Self-reporting healthy individuals.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
70
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
Pre-existing immune, cardiovascular or platelet disorders, diabetes mellitus, active malignancy, pregnancy, acute illness or vaccination within six weeks prior to recruitment, treatment with cardiovascular or immune-modulating medications within seven days prior to recruitment, or a previous adverse drug reaction to either Acetylsalicylic acid or ticagrelor.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
30/09/2024
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
30/11/2025
Query!
Actual
Query!
Date of last data collection
Anticipated
8/12/2025
Query!
Actual
Query!
Sample size
Target
20
Query!
Accrual to date
Query!
Final
Query!
Recruitment outside Australia
Country [1]
26383
0
New Zealand
Query!
State/province [1]
26383
0
Wellington
Query!
Funding & Sponsors
Funding source category [1]
316766
0
Charities/Societies/Foundations
Query!
Name [1]
316766
0
Wellington Medical Research Foundation
Query!
Address [1]
316766
0
Query!
Country [1]
316766
0
New Zealand
Query!
Primary sponsor type
University
Query!
Name
Victoria University of Wellington
Query!
Address
Query!
Country
New Zealand
Query!
Secondary sponsor category [1]
318980
0
None
Query!
Name [1]
318980
0
Query!
Address [1]
318980
0
Query!
Country [1]
318980
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
315533
0
Central Health and Disability Ethics Committee
Query!
Ethics committee address [1]
315533
0
https://ethics.health.govt.nz/about/central-health-and-disability-ethics-committee/
Query!
Ethics committee country [1]
315533
0
New Zealand
Query!
Date submitted for ethics approval [1]
315533
0
27/06/2024
Query!
Approval date [1]
315533
0
29/08/2024
Query!
Ethics approval number [1]
315533
0
2024 EXP 19948
Query!
Summary
Brief summary
The proposed study is to investigate whether neutrophils are affected by dual antiplatelet therapy. Platelets are blood clotting cells that usually act to repair damage to blood vessels. However, platelets also cause blood clotting in the arteries of the heart which can cause a heart attack. As such, dual antiplatelet therapy is the gold standard pharmacological management of a heart attack, which inhibits platelet activity to reduce the risk of recurrent cardiovascular events. Despite antiplatelet therapy, nearly a third of New Zealander’s will experience all-cause death, recurrent acute coronary syndrome (unstable angina or a heart attack), or will be readmitted to hospital due to their cardiovascular disease within 12 months of their heart attack. This recurrence is partially attributable to persistent platelet activity, although several studies have demonstrated that antiplatelet medications also elicit off-target effects on immune cells, which are known to be important for recovery after a heart attack. Neutrophils are the first type of immune cells to arrive to the site of cardiac injury after a heart attack, where they perform a variety of biological processes to clear debris and help recovery. Notably, the effects of antiplatelet therapy on neutrophils is understudied. Therefore we aim to investigate whether current antiplatelet medications have off-target effects on neutrophils. We hypothesise that dual anti-platelet therapy will affect neutrophil function.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
134994
0
Ms Ceridwyn Jones
Query!
Address
134994
0
Victoria University Clinical Research Laboratory, Level 8 CSB, Wellington Regional Hospital, 49 Riddiford Street, Newtown, Wellington 6021.
Query!
Country
134994
0
New Zealand
Query!
Phone
134994
0
+64273712175
Query!
Fax
134994
0
Query!
Email
134994
0
[email protected]
Query!
Contact person for public queries
Name
134995
0
Ceridwyn Jones
Query!
Address
134995
0
Victoria University Clinical Research Laboratory, Level 8 CSB, Wellington Regional Hospital, 49 Riddiford Street, Newtown, Wellington 6021.
Query!
Country
134995
0
New Zealand
Query!
Phone
134995
0
+64273712175
Query!
Fax
134995
0
Query!
Email
134995
0
[email protected]
Query!
Contact person for scientific queries
Name
134996
0
Ceridwyn Jones
Query!
Address
134996
0
Victoria University Clinical Research Laboratory, Level 8 CSB, Wellington Regional Hospital, 49 Riddiford Street, Newtown, Wellington 6021.
Query!
Country
134996
0
New Zealand
Query!
Phone
134996
0
+64273712175
Query!
Fax
134996
0
Query!
Email
134996
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF